drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (autologous CAR T cells)
drug_description
Autologous glypican-3 (GPC3)–targeted chimeric antigen receptor T-cell therapy. Patient T cells are engineered to express a CAR recognizing GPC3 on tumor cells; engagement activates CD3ζ with costimulatory signaling to drive T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPC3-positive hepatocellular carcinoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting glypican-3 (GPC3). Antigen engagement activates CD3ζ and costimulatory signaling, driving T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPC3-positive tumor cells (e.g., hepatocellular carcinoma).
drug_name
EU307 CAR-T Cell
nct_id_drug_ref
NCT05783570